Biotech Company** (Country) Pharma Company (Symbol/Country) Type/Product Area Amount Terms/Details (Month)
I. MODIFIED AGREEMENTS
Abgenix Inc. Pfizer Inc. (NYSE:PFE) Expansion of 12/97 collaboration and license agreement on use of Abgenix'sXenoMouse technology to make fully human antibodies to 3 of Pfizer's antigentargets $10M Pfizer exercised option for 2nd antigen target (undisclosed; 1st targetis for oncology applications); with exercise of option, Abgenix gets $10Min cash plus royalties (10/98)
Allelix Biopharmaceuticals Inc. (Canada) Eli Lilly and Co. (NYSE:LLY) Extension and expansion of partnership dating from 1989 on productsfor treating psychiatric, neurological and eating disorders ND Glutamate receptor program (for psychiatric and neurological disorders)has been extended for 2 years; genetic target program (for eating disorders)has been extended for 1 year (12/98)
ArQule Inc. Roche Bioscience (division of Roche Holding Ltd.; Switzerland) Amendment to 9/96 collaboration on new therapeutics via ArQule's directedarrays (custom libraries of compounds closely analogous to leads providedby Roche Bioscience) ND Companies will continue collaboration in a different form (not defined)through 3/99; ArQule will provide Roche with screening libraries whilecontinuing to optimize a number of Roche compounds (10/98)
Axys Pharmaceuticals Inc. Merck & Co. Inc. (NYSE:MRK) Extension of 11/96 collaboration on small molecule inhibitors of cathepsinK (cysteine protease) as therapies for osteoporosis ND Original agreement signed with Arris Pharmaceutical Corp. (which mergedwith Sequana Therapeutics Inc. in 1/98 to form Axys); companies extendedcollaboration to 11/99; further details ND (12/98)
Corixa Corp. SmithKline Beecham Major expansion of 10/95 $200M Expanded agreement adds 5 new vaccine
Biologicals SA collaboration on T cell- (equity; programs; SmithKline also has option to
(Belgium; unit of active vaccines for tuber- % ND) select 1 more application in future; 4-year
SmithKline Beecham culosis (amended 3/97 to collaboration; SmithKline licensed rights
plc; NYSE:SBH; U.K.) include antigens for use in to Corixa's HER-2/neu vaccine for breast
vaccines for breast and and ovarian cancer and its breast cancer
prostate cancer) to include antigen mammaglobin; except for tuber-
vaccines for ovarian and culosis vaccine, SmithKline gets exclusive
colon carcinoma as well as worldwide rights to all vaccine products;
for infectious diseases SmithKline also has option on nonexclusive
Chlamydia trachomatis license to Corixa's LeiF adjuvant and its
and C. pneumoniae microsphere delivery technology; Corixa
gets $49M committed funding over 4 years
(which includes a $2.5M equity purchase
now and $2.5M in the future, both at premi-
um); Corixa gets milestones of $150M, as
well as royalties; Corixa retains right to
form non-vaccine partnerships for these
antigens; transaction subject to antitrust
considerations (10/98)
Corvas Ortho Clinical Restructured agreement $1M Original 1992 agreement concerned
International Inc. Diagnostics Inc. that supercedes 1992 supply of thromboplastin formulations
(unit of Johnson & agreement for license to to Ortho; Corvas has now licensed the
Johnson; NYSE:JNJ) Corvas' recombinant diagnostic applications of its thrombo-
thromboplastin for use plastin; Ortho also gets certain licenses
in diagnostics related to production of recombinant
tissue factor; Corvas gets $1M for
these licenses and will continue to get
royalties (12/98)
Schering-Plough Extension of 6/97 $3M Schering-Plough will support preclinical
Corp. (NYSE:SGP) collaboration on oral development through 9/99 and provide
anticoagulants based on additional $3M in funding (12/98)
protease inhibitors
Gene Logic Inc. The Procter & Expansion of 6/97 ND Expansion will result in doubling of
Gamble Co. collaboration on thera- Gene Logic's annual revenues from
(NYSE:PG) peutic targets for heart collaboration; Procter & Gamble gets
failure (via Gene Logic's access to databases and will pay annual
READS gene expression fees; Gene Logic also gets milestones
technology for database of and royalties; the partners can now
differential gene expres- work together on any disease indication;
sion) to include target in Gene Logic can work with 3rd parties
osteoporosis on specific indications (12/98)
Rhone-Poulenc Expansion of 9/97 ND The original agreement was between
Rorer Inc. alliance to conduct p53 Rhone-Poulenc Rorer and OncorMed
(subsidiary of testing for clinical trials (which Gene Logic acquired in 9/98);
Rhone-Poulenc SA; of adenoviral p53 gene this is expansion of alliance to analyze
NYSE:RP; France) therapy for cancer genes for gene therapy clinical trials;
financial details ND (11/98)
GeneMedicine Inc. Merck & Co. Inc. Expansion of 12/97 ND Collaboration initially focused on 2
(NYSE:MRK) collaboration to evaluate therapeutic applications; it has now been
GeneMedicine's Gene- expanded to include 3 applications;
Switch technology (to further details ND (11/98)
control gene expression)
with Merck's vector system
for gene-based therapies
Genome Schering-Plough Acceleration of 12/96 ND Asthma genetics program is ahead of
Therapeutics Corp. (NYSE:SGP) collaboration to identify schedule; companies have enlarged
Corp. genes involved in suscep- program substantially and have moved
tibility to asthma up the time lines (11/98)
Incyte Pharma- Pfizer Inc. Expansion of 6/94 genom- ND Companies already extended and
ceuticals Inc. (NYSE:PFE) ic database partnership to expanded agreement in 2/98; now,
include Incyte's LifeTools Pfizer will use Incyte's LifeTools and
bioinformatics software LifeArray to support its global research
and LifeArray microarray programs; details ND (9/98)
data analysis and manage-
ment software
Inhale Therapeutic Baxter International Amendment of terms of ND Companies intend to find 3rd party to
Systems Inc. Inc. (NYSE:BAX) 3/96 collaboration to use further develop and commercialize
Inhale's dry-powder pul- an undisclosed compound; Baxter will
monary delivery system continue to provide funding in prepara-
for non-peptide, non- tion for Phase II trials while 3rd party
protein drug candidates is identified; product falls outside Bax-
ter's current business focus; other 2
compounds in collaboration will remain
and may be developed in future (10/98)
Medarex Inc. Merck KGaA Option to expand 4/94 $1.5M Merck paid $1.5M to obtain exclusive
(Germany) collaboration on Meda- option on worldwide licensing rights to
rex's MDX-477 bispecific product; Medarex would retain U.S.
antibody for certain cancers rights; Merck will fully fund Phase II
(targets epidermal growth trials (12/98)
factor receptor; currently
in Phase II trials for head
and neck cancer)
Microcide Ortho-McNeil Extension of 10/95 collab- ND Companies will continue joint develop-
Pharmaceuticals Pharmaceuticals and oration on therapeutics for ment of beta-lactam compounds; John-
Inc. the R.W. Johnson Gram-positive bacterial son & Johnson will support research
Pharmaceutical infections, especially drug- for additional 8-14 months; the duration
Research Institute resistant strains; focus on and amount of funding will depend on
(units of Johnson & beta-lactam compounds selection of 1 additional compound for
Johnson; NYSE:JNJ) development by 12/31/98; Microcide
regained rights to its antibiotic potentia-
tor technologies and compounds (10/98)
Myriad Genetics Bayer Corp. Extension of 9/95 alliance $12.2M Bayer extended collaboration until 9/02;
Inc. (unit of Bayer AG; to discover genes that Myriad has made significant progress
Germany) predispose individuals to toward isolating disease-causing genes;
obesity, osteoporosis and Myriad will get additional $6.2M in
asthma committed research funds plus $6M in
milestones over next 2 years (12/98)
Neurogen Corp. Pfizer Inc. Extension and expansion $12.5M Collaboration extended for 2 years;
(NYSE:PFE) of collaborations on small- Neurogen gets $6.25M per year in
molecule drugs that act on additional research funds (11/98)
specific GABA receptors
in brain; on drugs for
anxiety and cognition
(from 2/92) and drugs for
sleep disorders (from 6/94);
added depression as new
target
Xenova Group Parke-Davis Extension of 5/97 drug ND Xenova provided natural product extracts
plc (U.K.) (division of discovery collaboration for screening, which Parke-Davis has done,
Warner-Lambert based on Xenova's identifying potential hits from which
Co.; NYSE:WLA) NatChem natural products Xenova will now isolate and identify
library active chemicals; Xenova gets certain
additional payments (10/98)
II. TERMINATED AGREEMENTS
Alkermes Inc. The R.W. Johnson Termination of 12/96 Companies reached mutual decision to
Pharmaceutical collaboration on use of terminate collaboration; Alkermes
Research Institute Alkermes' ProLease drug regains all rights licensed to Pharma-
(unit of Johnson & delivery system to develop ceutical Research Institute, which has
Johnson; NYSE:JNJ) sustained-release formula- discontinued product development
tion of undisclosed drug (11/98)
for treating hormone-
mediated disorders
Schering-Plough Termination of 1/92 Companies reached mutual decision
Corp. (NYSE:SGP) agreement on use of to terminate collaboration; Alkermes
Alkermes' ProLease drug regains all rights licensed to Schering-
delivery system to develop Plough; further details ND (11/98)
sustained-release formula-
tion of Intron A (recombi-
nant interferon alfa-2b)
Allelix Biopharma- Astra AB Termination of 6/96 As a result of corporate restructuring
ceuticals Inc. (Sweden) agreement to develop at Astra, this program no longer fits;
(Canada) ALX1-11 (recombinant Allelix reacquired all product rights,
human parathyroid including assets, know-how and pro-
hormone) for treating prietary rights; Allelix will assume
osteoporosis (currently responsibility for product development
in Phase II trials) (9/98)
Ergo Science The R.W. Johnson Termination of 2/98 FDA denied approval of Ergoset in
Corp. Pharmaceutical collaboration on 11/98, after which Johnson & Johnson
Research Institute Ergoset Tablets (bromo- terminated collaboration (12/98)
and Ortho-McNeil criptine mesylate; dopa-
Pharmaceutical Inc. mine agonist) and other
(units of Johnson products for treating
& Johnson; NYSE:JNJ) Type II diabetes and
obesity
Inex Pharma- Schwarz Pharma Termination of 3/98 Drug failed to show benefit in Phase II
ceuticals Corp. AG (Germany) collaboration to develop trial; companies discontinued develop-
(TSE:IEX; Canada) antisense drug INX-3280 ment in Europe and North America;
(blocks function of c-myc Inex will not continue product develop-
gene) for treating cardio- ment on its own (10/98)
vascular restenosis
Intercardia Inc. Astra Pharma- Termination of 12/95 As a result of corporate restructuring at
ceuticals LP agreement on Bextra Astra (it bought out Merck's share of Astra
(formerly Astra (bucindolol HCl) for Merck), Astra's product line now includes
Merck Inc.) treating congestive heart a competing product (Toprol-XL); agreement
failure (currently in terminated by mutual agreement, due to
Phase III trials) non-compete clause in terms of original
deal; Intercardia regains all rights, material
and information relating to product,
plus termination fee (9/98)
NeoRx Corp. Janssen Termination of 8/97 Janssen will terminate agreement at
Pharmaceutica NV collaboration on NeoRx's year-end 1998, but is currently com-
(Belgium; unit of radioimmunotherapy prod- pleting Phase II trials in advanced
Johnson & Johnson; uct Avicidin (for treating colon and prostate cancer; patients
NYSE:JNJ) solid tumors) exhibited high incidence of unaccept-
able diarrhea; all rights to product and
underlying pretargeting technology
revert to NeoRx, along with all data
generated by study (9/98)
Schwarz Pharma Termination of 4/97 Schwarz ceased product development,
AG (Germany) collaboration on NeoRx's citing need for more studies with a new
Biostent (combination catheter and delays in the project;
drug/device) for treating NeoRx has no plans to conduct Phase II
restenosis following trials without a partner (11/98)
balloon angioplasty
(Phase I trials completed)
Sonus Pharma- Daiichi Termination of 3/95 Daiichi took product through Phase I
ceuticals Inc. Pharmaceutical license agreement on trials in Japan, completed in 12/97, but
Co. Ltd. (Japan) EchoGen ultrasound no further clinical development since
contrast agent for intra- that time; Sonus terminated agreement
venous myocardial con- and is seeking another development
trast echocardiography partner (11/98)
NOTES:
# This chart contains information on modified and terminatedagreements only, covering the time period between 9/23/98 and 12/24/98.It does not include arrangements that are classed strictly as production,marketing and/or distribution agreements, nor does it include any collaborationsthat involve agricultural product development.
For a chart listing new collaborations between biotechcompanies and big pharma for the same time period (9/23/98 ­ 12/24/98),see the 1/4/99 issue of BioWorld Financial Watch.
ND = Not disclosed, reported and/or available; TSE = TorontoStock Exchange
* Private companies are indicated with an asterisk.
** Unless otherwise notes, the trading symbols for publicbiotechnology companies can be found by referring to the BioWorld Stockreport For Public Biotechnology Companies on pp. 12-13.